Advanced in Ewing Sarcoma

Dr. Sharon A. Spencer

Radiation Oncology
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
 (2075.5 mi)
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Advanced in Ewing Sarcoma
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
 (2075.5 mi)
OverviewInsuranceLocationsClinical Research

Overview

Sharon Spencer is a Radiation Oncologist in Birmingham, Alabama. Dr. Spencer and is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Laryngeal Cancer, Throat Cancer, Oral Squamous Cell Carcinoma, Lung Cancer, and Gastrostomy. Dr. Spencer is currently accepting new patients.

Her clinical research consists of co-authoring 74 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Humana

Locations

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35249

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Other, Procedure, Drug, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 09, 2024
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 03, 2024
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients With Head and Neck Cancer Receiving Radiation Therapy With or Without Concurrent Chemotherapy
Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients With Head and Neck Cancer Receiving Radiation Therapy With or Without Concurrent Chemotherapy
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2024
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 08, 2024
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
View 8 Less Clinical Trials

74 Total Publications

Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.
Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.
Journal: Practical radiation oncology
Published: April 30, 2024
Similar Doctors
Advanced in Ewing Sarcoma
Dr. Michael C. Dobelbower
Radiation Oncology | Oncology
Advanced in Ewing Sarcoma
Dr. Michael C. Dobelbower
Radiation Oncology | Oncology

Uca Specialty Pharmacy

3485 Independence Dr, 
Homewood, AL 
 (2.6 mi)
205-930-0920
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Dobelbower is a Radiation Oncologist and an Oncologist in Homewood, Alabama. Dr. Dobelbower and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Lung Cancer, Meningioma, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Gastrostomy. Dr. Dobelbower is currently accepting new patients.

Experienced in Ewing Sarcoma
Dr. Markus Bredel
Radiation Oncology
Experienced in Ewing Sarcoma
Dr. Markus Bredel
Radiation Oncology
1700 6th Ave S, 
Birmingham, AL 
 (0.2 mi)
205-934-5670
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients

Markus Bredel is a Radiation Oncologist in Birmingham, Alabama. Dr. Bredel and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Thalamotomy, and Gamma Knife Radiosurgery. Dr. Bredel is currently accepting new patients.

Experienced in Ewing Sarcoma
Dr. Rojymon Jacob
Radiation Oncology
Experienced in Ewing Sarcoma
Dr. Rojymon Jacob
Radiation Oncology
1717 6th Ave S, 
Birmingham, AL 
 (0.1 mi)
800-822-8816
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rojymon Jacob is a Radiation Oncologist in Birmingham, Alabama. Dr. Jacob and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Pancreatic Cancer, Prostate Cancer, Familial Prostate Cancer, and Familial Pancreatic Cancer. Dr. Jacob is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile